In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are ...
Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...
Raj Indupuri, CEO, eClinical Solutions, touched on how AI can significantly enhance risk identification and mitigation in clinical trials by enabling integrated, data-driven quality management from ...
In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...
Novo Nordisk’s amended proposal values Metsera at $86.20-per-share, for a total value upwards of $10 billion, representing an ...
Recent partnership announcements in the pharma industry reflects the community’s commitment to collaborative innovation, ...
In the third entry of Pharmacuetical Executive’s premium webinar series examining the impact of President Trump’s MFN ...
Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI ...
In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...
See how leading teams are achieving measurable impact in just 90 days—without adding validation debt or manual, swivel-chair workflows. Purpose-built, inspection-ready platforms now outpace custom ...
The final session of Pharmaceutical Executive’s and MJH Life Sciences’ three-part webinar series on President Trump’s “Most ...
UCB has announced FDA’s approval of Kygevvi (doxecitine and doxribtimine) for the treatment of adults and pediatric patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback